Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Minerva Neurosciences Inc. currently manages 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 4 actions are distributed among 4 distinct examiners, so no examiner is handling more than one pending matter. The portfolio is also spread across 4 distinct art units, indicating that each action is being reviewed by a separate technical division within the patent office. This 4 distinct art units count shows distribution in the prosecution process.
The busiest examiner is RODRIGUEZ, RAYNA B, who is responsible for 1 busiest examiner pending office action. This 1 busiest examiner pending office action is one of the 4 pending office actions total. Because the 4 distinct examiners are assigned to these actions, there is no centralization of prosecution for this portfolio. Practitioners must manage separate interactions across the 4 distinct art units. The 1 busiest examiner pending office action for RODRIGUEZ, RAYNA B is representative of the workload assigned to each examiner involved in the Biotechnology & Pharmaceuticals area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Double-patenting only | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RODRIGUEZ, RAYNA B | 1 | 33.6% | +19.2% |
| NEAGU, IRINA | 1 | 46.7% | +57.2% |
| RICCI, CRAIG D | 1 | 53.7% | +52.6% |
| NOLAN, JASON MICHAEL | 1 | 66.6% | -27.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18764714 | METHODS OF USE OF PHENOXYPROPYLAMINE COMPOUNDS TO TREAT DEPRESSION | NEAGU, IRINA | — |
| 18168028 | USE OF ROLUPERIDONE IN PREVENTING RELAPSE IN SCHIZOPHRENIA PATIENTS | NOLAN, JASON MICHAEL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18821656 | METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SCHIZOPHRENIA | RODRIGUEZ, RAYNA B | — |
| 18764714 | METHODS OF USE OF PHENOXYPROPYLAMINE COMPOUNDS TO TREAT DEPRESSION | NEAGU, IRINA | — |
| 18647374 | SIGMA LIGAND COMPOUNDS AND USES THEREOF | RICCI, CRAIG D | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1629 | 1 |
| 1611 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18821656 | METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SCHIZOPHRENIA | RODRIGUEZ, RAYNA B | 1628 | DP | Non-Final OA | — | Pending | Aug 30, 2024 |
| 18764714 | METHODS OF USE OF PHENOXYPROPYLAMINE COMPOUNDS TO TREAT DEPRESSION | NEAGU, IRINA | 1629 | §103§112 | Non-Final OA | — | Pending | Jul 05, 2024 |
| 18647374 | SIGMA LIGAND COMPOUNDS AND USES THEREOF | RICCI, CRAIG D | 1611 | §112 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18168028 | USE OF ROLUPERIDONE IN PREVENTING RELAPSE IN SCHIZOPHRENIA PATIENTS | NOLAN, JASON MICHAEL | 1623 | §103§112 | Non-Final OA | — | Pending | Feb 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMinerva Neurosciences Inc. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Rayna B Rodriguez has the most, with 1 of Minerva Neurosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
